Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Globus Medical (NYSE:GMED) in the last three months.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $96.0, along with a high estimate of $115.00 and a low estimate of $83.00. This current average reflects an increase of 11.63% from the previous average price target of $86.00.

Interpreting Analyst Ratings: A Closer Look

A clear picture of Globus Medical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Globus Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Globus Medical analyst ratings.

Get to Know Globus Medical Better

Understanding the Numbers: Globus Medical's Finances

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Globus Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 63.1% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Globus Medical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.28%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Globus Medical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.29%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.03%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.